The Green Cross Corporation

Samsung Electronics Co., Ltd.

Musicmob Co., Ltd.

Mi-Soon Kim

Hee Jeong Seo

Min Ju Kim

Eun-Jung Park

Soongyu Choi

Younggyu Kong

Myung Eun Jung

Suk Ho Lee

Kwang-Seop Song

So Ok Park

Hyun Jung Kim

Min Woo Lee

Kisoo Park

Ickhwan Son

Man-Young Cha

Jinhwa Lee

Jeongmin Kim

Kinam Lee

Sang-ho Ma

Hyunku Kang

Jun Sung Lee

Suk Hoon Kang

Dong Hyuk Jang

Sung-Han Lee

Dong Ho Hong

Jangwon Hong

Sang Mi Kang

Misuk Kang

Jung-Hun Lee

Ae Nim Pae

Jong-Mu Choi

Jae Eun Kim

Woo-Kyu Park

Jun-Yeop Jung

Jong Yup Kim

Eun Jung Son

Ho Kyun Han

Heon-Joo Jun

Ki-Nam Lee

Kwang Seop Song

Min-Ah Kim

Hee-Jung Chae

Kwang Woo Ahn

The present invention provides an apparatus, system and method for reproducing data in groups. According to the apparatus, system and method for reproducing data in groups, some piece of data of sound source data that is already being reproduced through a specific terminal or external speaker is input through a microphone and compared with the entire data of the sound source data, thus to identify a current reproduction point, and synchronize the reproduction point with sound source data being played externally, thereby reproducing the sound source data at the same time.

Data group playback device and system and method for same

Provided is pyrazole derivatives as a TNIK (Traf2- and NCK-interacting kinase), IKK&#x3b5; (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits TNIK, IKK&#x3b5; and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

Pyrazole derivatives as TNIK, IKK&#x3f5; and TBK1 inhibitor and pharmaceutical composition comprising same

Provided are 7-azaindole or 4,7-diazaindole derivatives as an IKK&#x3b5; (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor. The 7-azaindole or 4,7-diazaindole derivative effectively inhibits IKK&#x3b5; and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

7-azaindole or 4,7-diazaindole derivatives as IKK&#x3f5; epsilon and TBK1 inhibitor and pharmaceutical composition comprising same

Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKK&#x3b5; (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKK&#x3b5; and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

Compounds as TNIK, IKK&#x3b5; and TBK1 inhibitors and pharmaceutical composition comprising same

A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.

Diphenylmethane derivatives as SGLT2 inhibitors

The present invention relates to a method for dual inhibition of sodium-dependent glucose cotransporter 1 (SGLT1) and sodium-dependent glucose cotransporter 2 (SGLT2) present in the intestine and kidney by using the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof: wherein ring A, ring B, X and Y have the same meanings as defined in the specification.

Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives

A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.

Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same

A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.

C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same

Provided is an apparatus and method for saving power in a dual mode portable terminal that concurrently supports a cellular network and an unlicensed band network. The method includes, upon disassociating from an in-association Access Point (AP) of an unlicensed band network, measuring a Received Signal Strength Indicator (RSSI) from the AP during a predetermined time and calculating an average value of the RSSI; and comparing the calculated average value with a predetermined threshold value and deciding whether to perform a mode conversion between a low power mode and a general mode.

Apparatus and method for saving power in dual mode portable terminal

A novel sulfur containing heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CBreceptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provide a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.

Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists

Growing community of inventors

Yongin-si, South Korea

Mi-Soon Kim